Eficácia e Segurança de Bimekizumabe em Pacientes com Artrite Psoriásica Ativa: resultados de três anos de um estudo de fase IIb randomizado controlado e seu estudo de extensão aberto
Arthritis Rheumatol. 2022 doi: 10.1002/art.42280
This study highlighted that the safety of bimekizumab in patients with PsA over 3 years of treatment was consistent with the previous 48-week results, as well as other recently published studies of IL-17 inhibitors in PsA patients.